Skip to main content
Premium Trial:

Request an Annual Quote

CRISPR Therapeutics Inks Licensing, Collaboration Deal With Anagenesis Biotechnologies

NEW YORK (GenomeWeb) – CRISPR Therapeutics has signed a licensing and collaboration deal with France's Anagenesis Biotechnologies.

Under the terms of the agreement, CRISPR Therapeutics will receive an exclusive worldwide license to use Anagenesis' proprietary paraxial mesodermic multipotent cells (P2MCs) for cell therapy and for all human muscle diseases. P2MCs allows for the efficient, reproducible and chemically defined differentiation of pluripotent cells into skeletal muscle stem cells. CRISPR Therapeutics said the collaboration will initially focus on Duchenne Muscular Dystrophy (DMD).

"Bringing together the CRISPR gene-editing platform with the P2MC technology enables us to develop ex vivo therapeutic approaches for the treatment of DMD using muscle satellite stem cells," CRISPR Therapeutics CSO Bill Lundberg said in a statement.

Financial and other terms of the agreement were not disclosed.

The deal is the third in a string of collaborations for CRISPR Therapeutics. In recent months, the Basel, Switzerland-based firm has also signed agreements with Bayer and Vertex Pharmaceuticals.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.